两种不同剂型的1,6-二磷酸果糖在冠心病心绞痛治疗中的最小成本分析

Minimum Cost Analysis about Two Different Types of 1,6-two Phosphoric Acid Fructose in the Treatment of Coronary Disease

目的比较两种不同剂型的1,6-二磷酸果糖(FDP)在冠心病心绞痛治疗中的疗效及成本。方法运用药物经济学最小成本分析法,分别对两种不同剂型的FDP在冠心病心绞痛治疗中的临床疗效及成本进行评价。结果两组治疗结果的总有效率分别为A组:85.0%,B组:82.9%,差异无显著性(P>0.05);A组和B组的治疗成本分别为857.9元,1233.8元,A组低于B组30.5%。结论从药物经济学角度看,A组方案为两组方案中的优选方案。

Objective Comparison of efficiency and cost of two different types of 1,6-two phosphoric acid fructose in the treatment of coronary heart disease. Methods The use of drugs economics minimum cost analysis, respectively, to evaluate two different types of 1,6-two phosphoric acid fructose in the treatment of coronary heart disease in clinical efficacy and cost. Results The overall efficiency of treatment outcome respectively, Group A： 85.0%,Group B： 82. 9%, no significant differences in sex （P〉0.05）. Group A and Group B treatment cost respectively, Group A： 857.9 yuan, Group B. 1233.8 yuan. Group A below Group B 30.5%. Conclusions From drug economics perspective, Group A programme is a perfect programme.